Factors affecting HBV DNA suppression in chronic hepatitis B patients treated with tenofovir disoproxil fumarate [version 2; peer review: 2 approved]
Background: This study aims to determine the factors affecting HBV DNA suppression in chronic hepatitis B patients with tenofovir disoproxil fumarate (TDF). Methods: A case-control was carried out from October 2021 to August 2022 on 182 chronic hepatitis B patients who had TDF therapy regularly for...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
F1000 Research Ltd
2023-08-01
|
| Series: | F1000Research |
| Subjects: | |
| Online Access: | https://f1000research.com/articles/11-1521/v2 |
| _version_ | 1797685397933785088 |
|---|---|
| author | Putri Chairani Eyanoer Masrul Lubis Mustafa Mahmud Amin Fauzi Yusuf Tri Widyawati Muhammad Rusda Dharma Lindarto Jelita Siregar Imelda Rey Darmadi Darmadi |
| author_facet | Putri Chairani Eyanoer Masrul Lubis Mustafa Mahmud Amin Fauzi Yusuf Tri Widyawati Muhammad Rusda Dharma Lindarto Jelita Siregar Imelda Rey Darmadi Darmadi |
| author_sort | Putri Chairani Eyanoer |
| collection | DOAJ |
| description | Background: This study aims to determine the factors affecting HBV DNA suppression in chronic hepatitis B patients with tenofovir disoproxil fumarate (TDF). Methods: A case-control was carried out from October 2021 to August 2022 on 182 chronic hepatitis B patients who had TDF therapy regularly for 24 weeks at H. Adam Malik and USU Hospitals in Medan, Indonesia. The history of the samples was obtained, followed by physical examination, and blood collection. CTLA-4 polymorphism examination was carried out using real-time PCR, while the serum CTLA-4 levels were assessed with ELISA. Results: The CTLA-4 -1661G>A polymorphism, genotype GG+AG, increased 1.52 times risk of not achieving HBV DNA suppression to TDF compared to genotype AA (p=0.041). High CTLA-4 levels increased 2.28 times risk, high HBV DNA levels increased 2.09 times risk, low ALT levels increased 1.95 times risk of not achieving HBV DNA suppression (p= 0.009, 0.026, 0.036, respectively). There was no relationship between gender, age, ethnicity, obesity, baseline AST, HBeAg, genotype, liver fibrosis and HBV DNA suppression after 24 weeks of treatment (p>0.05). Conclusions: The levels of CTLA-4, HBV DNA, ALT, and CTLA-4 -1661G>A polymorphism have a potential relationship with the suppression of HBV DNA in chronic hepatitis B patients with TDF. |
| first_indexed | 2024-03-12T00:43:35Z |
| format | Article |
| id | doaj.art-d6f3048357b94612b312a85927decd47 |
| institution | Directory Open Access Journal |
| issn | 2046-1402 |
| language | English |
| last_indexed | 2024-03-12T00:43:35Z |
| publishDate | 2023-08-01 |
| publisher | F1000 Research Ltd |
| record_format | Article |
| series | F1000Research |
| spelling | doaj.art-d6f3048357b94612b312a85927decd472023-09-15T00:00:02ZengF1000 Research LtdF1000Research2046-14022023-08-0111154811Factors affecting HBV DNA suppression in chronic hepatitis B patients treated with tenofovir disoproxil fumarate [version 2; peer review: 2 approved]Putri Chairani Eyanoer0Masrul Lubis1Mustafa Mahmud Amin2Fauzi Yusuf3https://orcid.org/0000-0002-5822-300XTri Widyawati4https://orcid.org/0000-0001-6230-6943Muhammad Rusda5Dharma Lindarto6Jelita Siregar7Imelda Rey8Darmadi Darmadi9https://orcid.org/0000-0001-5281-168XDepartment of Public Health, Faculty of Medicine, Universitas Sumatera Utara, Medan, North Sumatera, 20155, IndonesiaDepartment of Internal Medicine, Faculty of Medicine, Universitas Sumatera Utara, Medan, North Sumatera, 20155, IndonesiaPhilosophy Doctor in Medicine Program, Faculty of Medicine, Universitas Sumatera Utara, Medan, North Sumatera, 20155, IndonesiaDepartment of Internal Medicine, Faculty of Medicine, Universitas Syiah Kuala, Banda Aceh, Aceh, 23111, IndonesiaDepartment of Pharmacology and Therapeutic, Faculty of Medicine, Universitas Sumatera Utara, Medan, North Sumatera, 20155, IndonesiaPhilosophy Doctor in Medicine Program, Faculty of Medicine, Universitas Sumatera Utara, Medan, North Sumatera, 20155, IndonesiaDepartment of Internal Medicine, Faculty of Medicine, Universitas Sumatera Utara, Medan, North Sumatera, 20155, IndonesiaDepartment of Clinical Pathology, Faculty of Medicine, Universitas Sumatera Utara, Medan, North Sumatera, 20155, IndonesiaDepartment of Internal Medicine, Faculty of Medicine, Universitas Sumatera Utara, Medan, North Sumatera, 20155, IndonesiaDepartment of Internal Medicine, Faculty of Medicine, Universitas Sumatera Utara, Medan, North Sumatera, 20155, IndonesiaBackground: This study aims to determine the factors affecting HBV DNA suppression in chronic hepatitis B patients with tenofovir disoproxil fumarate (TDF). Methods: A case-control was carried out from October 2021 to August 2022 on 182 chronic hepatitis B patients who had TDF therapy regularly for 24 weeks at H. Adam Malik and USU Hospitals in Medan, Indonesia. The history of the samples was obtained, followed by physical examination, and blood collection. CTLA-4 polymorphism examination was carried out using real-time PCR, while the serum CTLA-4 levels were assessed with ELISA. Results: The CTLA-4 -1661G>A polymorphism, genotype GG+AG, increased 1.52 times risk of not achieving HBV DNA suppression to TDF compared to genotype AA (p=0.041). High CTLA-4 levels increased 2.28 times risk, high HBV DNA levels increased 2.09 times risk, low ALT levels increased 1.95 times risk of not achieving HBV DNA suppression (p= 0.009, 0.026, 0.036, respectively). There was no relationship between gender, age, ethnicity, obesity, baseline AST, HBeAg, genotype, liver fibrosis and HBV DNA suppression after 24 weeks of treatment (p>0.05). Conclusions: The levels of CTLA-4, HBV DNA, ALT, and CTLA-4 -1661G>A polymorphism have a potential relationship with the suppression of HBV DNA in chronic hepatitis B patients with TDF.https://f1000research.com/articles/11-1521/v2CTLA-4 HBV DNA Hepatitis B Polymorphism Tenofovireng |
| spellingShingle | Putri Chairani Eyanoer Masrul Lubis Mustafa Mahmud Amin Fauzi Yusuf Tri Widyawati Muhammad Rusda Dharma Lindarto Jelita Siregar Imelda Rey Darmadi Darmadi Factors affecting HBV DNA suppression in chronic hepatitis B patients treated with tenofovir disoproxil fumarate [version 2; peer review: 2 approved] F1000Research CTLA-4 HBV DNA Hepatitis B Polymorphism Tenofovir eng |
| title | Factors affecting HBV DNA suppression in chronic hepatitis B patients treated with tenofovir disoproxil fumarate [version 2; peer review: 2 approved] |
| title_full | Factors affecting HBV DNA suppression in chronic hepatitis B patients treated with tenofovir disoproxil fumarate [version 2; peer review: 2 approved] |
| title_fullStr | Factors affecting HBV DNA suppression in chronic hepatitis B patients treated with tenofovir disoproxil fumarate [version 2; peer review: 2 approved] |
| title_full_unstemmed | Factors affecting HBV DNA suppression in chronic hepatitis B patients treated with tenofovir disoproxil fumarate [version 2; peer review: 2 approved] |
| title_short | Factors affecting HBV DNA suppression in chronic hepatitis B patients treated with tenofovir disoproxil fumarate [version 2; peer review: 2 approved] |
| title_sort | factors affecting hbv dna suppression in chronic hepatitis b patients treated with tenofovir disoproxil fumarate version 2 peer review 2 approved |
| topic | CTLA-4 HBV DNA Hepatitis B Polymorphism Tenofovir eng |
| url | https://f1000research.com/articles/11-1521/v2 |
| work_keys_str_mv | AT putrichairanieyanoer factorsaffectinghbvdnasuppressioninchronichepatitisbpatientstreatedwithtenofovirdisoproxilfumarateversion2peerreview2approved AT masrullubis factorsaffectinghbvdnasuppressioninchronichepatitisbpatientstreatedwithtenofovirdisoproxilfumarateversion2peerreview2approved AT mustafamahmudamin factorsaffectinghbvdnasuppressioninchronichepatitisbpatientstreatedwithtenofovirdisoproxilfumarateversion2peerreview2approved AT fauziyusuf factorsaffectinghbvdnasuppressioninchronichepatitisbpatientstreatedwithtenofovirdisoproxilfumarateversion2peerreview2approved AT triwidyawati factorsaffectinghbvdnasuppressioninchronichepatitisbpatientstreatedwithtenofovirdisoproxilfumarateversion2peerreview2approved AT muhammadrusda factorsaffectinghbvdnasuppressioninchronichepatitisbpatientstreatedwithtenofovirdisoproxilfumarateversion2peerreview2approved AT dharmalindarto factorsaffectinghbvdnasuppressioninchronichepatitisbpatientstreatedwithtenofovirdisoproxilfumarateversion2peerreview2approved AT jelitasiregar factorsaffectinghbvdnasuppressioninchronichepatitisbpatientstreatedwithtenofovirdisoproxilfumarateversion2peerreview2approved AT imeldarey factorsaffectinghbvdnasuppressioninchronichepatitisbpatientstreatedwithtenofovirdisoproxilfumarateversion2peerreview2approved AT darmadidarmadi factorsaffectinghbvdnasuppressioninchronichepatitisbpatientstreatedwithtenofovirdisoproxilfumarateversion2peerreview2approved |